AbbVie's 8-week HCV regimen approved in the U.S. and EU

FDA approved Mavyret glecaprevir/pibrentasvir from AbbVie Inc. (NYSE:ABBV) to treat chronic HCV genotypes 1-6 infection in previously untreated adults without cirrhosis or with compensated cirrhosis. The fixed-dose combination is also indicated for HCV genotype 1 infection in adults previously treated with a regimen containing either an HCV NS5A protein inhibitor or an HCV NS3/4A protease inhibitor.

FDA said Mavyret is the first 8-week treatment regimen approved for all 6 HCV genotypes in previously untreated adults without cirrhosis; standard treatment length was previously 12 weeks or more...